HDACi prevent breast tumor progression via transcriptional inhibition of EMT-related genes, modulation of human epidermal growth factor receptor 2 (HER2) expression or induction of estrogen receptor (ER) in hormone receptor-negative tumors, as well as by increasing the sensitivity of hormonal therapy in ER positive tumors [142]. This evidence concerns the gene ERBB2 and breast neoplasm.